[Hearing disorders in children less than 16 months of age after bacterial meningitis with reference to cerebrospinal fluid elastase].
Hearing impairment as a sequela of acute bacterial meningitis is a well known complication. Dexamethasone therapy in addition to antibiotics is beneficial in the reduction of deafness, implicating that inflammation may be one reason for hearing impairment. The risk of hearing impairment in different types of bacterial meningitis is well studied. In very young children < 1.5 years of life the incidence of hearing loss and the possible correlation of laboratory data with the development of deafness is yet unknown. We therefore examined the brainstem auditory evoked potentials in 25 children between the first month and the 16th month of life who we treated for meningitis during 3 years in our hospital. 11 children were treated with dexamethasone. In 9 children we found abnormal brainstem auditory evoked potentials, which we controlled every 3 months. 7 children had transient conductive hearing impairment with good recovery during the first year after the disease. In 2 cases we found permanent bilateral sensorineural hearing loss. There was a significant relationship between hearing loss and elastase in cerebrospinal fluid. Dexamethasone reduced this relationship. A screening of hearing should be performed as routine control in all patients with acute meningitis. The association of high elastase in cerebrospinal fluid and later hearing impairment indicates a pathophysiological relation between activation of granulocytes and hearing loss.
Wilken
B
B
Klinik für Pdiatrie, Medizinische Universität zu Lübeck.
van Wees
J
J
Tegtmeyer
F K
FK
Aksu
F
F
D000900:Anti-Bacterial Agents; D001309:Auditory Threshold / Q000187:drug effects / Q000502:physiology; D001933:Brain Stem / Q000187:drug effects / Q000503:physiopathology; D003638:Deafness / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D006314:Hearing Loss, Conductive / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007223:Infant; D008297:Male; D016920:Meningitis, Bacterial / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D010196:Pancreatic Elastase / Q000134:cerebrospinal fluid*; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D003907:Dexamethasone; D010196:Pancreatic Elastase
Hörstörungen bei Kindern unter 16 Monaten nach bakterieller Meningitis unter Berücksichtigung der Liquorelastase.